Author:
Yeni P,LaMarca A,Berger D,Cimoch P,Lazzarin A,Salvato P,Smaill FM,Teofilo E,Madison SJ,Nichols WG,Adkison KK,Bonny T,Millard J,McCarty D,
Subject
Pharmacology (medical),Infectious Diseases,Health Policy
Reference23 articles.
1. 1 Poignard P , Saphire EO , Parren PW , Burton DR. gp120: biologic aspects of structural features. Annu Rev Immunol 2001; 19: 253-274.
2. 2 Huang Y , Paxton WA , Wolinsky SM et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2: 1240-1243.
3. 3 Patricia D'Souza M , Harden V. Chemokines and HIV-1 second receptors. Nat Med 1996; 2: 1293-1300.
4. 4 Maeda K , Nakata H , Miyakawa T et al. Spirodiketopiperazine-based CCR5 inhibitor, which preserves CC chemokine/CCR5 interactions and exerts potent activity against R5 HIV type 1 in vitro. J Virol 2004; 78: 8654-8662.
5. 5 Nakata H , Maeda K , Kawano Y et al. Potent in vivo anti-R5HIV effects of AK602, a novel spirodiketopiperazine (SPD)-containing HIV-specific CCR5 inhibitor, in hu-PBMC-NOD-mice. 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2003 [Abstract 564a].
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献